Convatec Group (FRA:2CV) Other Current Receivables: €25 Mil (As of Dec. 2025)


FRA:2CV Convatec Group PLC FRA:2CV
77 GF Score
Price €2.52
GF Value €2.98
! 4 Warning Signs
View Full Analysis

What is Convatec Group Other Current Receivables?

Convatec Group FRA:2CV +5.00% 77 Other Current Receivables is €25 Mil as of Dec. 2025. GuruFocus rates FRA:2CV with a GF Score™ of 77/100 and a GF Value™ of €2.98. The stock has 4 warning signs investors should review.

Convatec Group's Other Current Receivables for the quarter that ended in Dec. 2025 was €25 Mil.

Convatec Group's quarterly Other Current Receivables declined from Dec. 2024 (€16.24 Mil) to Jun. 2025 (€0.00 Mil) but then increased from Jun. 2025 (€0.00 Mil) to Dec. 2025 (€24.77 Mil).

Convatec Group's annual Other Current Receivables declined from Dec. 2023 (€35.76 Mil) to Dec. 2024 (€16.24 Mil) but then increased from Dec. 2024 (€16.24 Mil) to Dec. 2025 (€24.77 Mil).

Convatec Group Other Current Receivables Related Terms

Convatec Group Other Current Receivables Historical Data

* Premium members only.

The historical data trend for Convatec Group's Other Current Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Convatec Group Other Current Receivables Chart

Convatec Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 45.05 27.85 35.76 16.24 24.77

Convatec Group Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 35.76 0.00 16.24 0.00 24.77
FRA:2CV
77GF Score
Convatec Group PLC FRA:2CV
Other Current Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Convatec Group Other Current Receivables Calculation

GuruFocus uses a standardized financial statement format for all companies. GuruFocus lists Accounts Receivable, Notes Receivable , Loans Receivable and Other Current Receivables under the "Total Receivables" section.

What does a Other Current Receivables of €25 Mil mean?
Convatec Group (FRA:2CV) has a Other Current Receivables of €25 Mil as of Dec. 2025. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Convatec Group and its competitors.
Is Convatec Group's Other Current Receivables too high?
Convatec Group's current Other Current Receivables is €25 Mil. Overall, Convatec Group has a GF Score™ of 77/100, reflecting its overall financial health beyond just this single metric.
How does Convatec Group's Other Current Receivables compare to ISRG and BDX?
Convatec Group's Other Current Receivables of €25 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Receivables for a Medical Devices & Instruments company?
A good Other Current Receivables depends on the Medical Devices & Instruments industry context. However, Other Current Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Receivables mean?
A high Other Current Receivables can signal that a stock is expensive relative to its fundamentals. Other Current Receivables is other current receivables of that not otherwise classified. View historical data on Convatec Group and its competitors. Convatec Group's current Other Current Receivables is €25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Convatec Group stock overvalued right now?
Convatec Group (FRA:2CV) has a current Other Current Receivables of €25 Mil. The stock's GF Value™ is €2.98, compared to a current price of €2.52 — trading 15.4% below its estimated fair value. The current Other Current Receivables is €25 Mil. Convatec Group's overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Receivables calculated?
Other Current Receivables is calculated from a company's financial statements. For Convatec Group (FRA:2CV), the current Other Current Receivables is €25 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Convatec Group (FRA:2CV) Overvalued in 2026?

Based on GuruFocus' analysis, Convatec Group stock appears to be undervalued. The current stock price of €2.52 is trading 15.4% below its estimated GF Value™ of €2.98.

Key valuation signals for FRA:2CV:

  • Other Current Receivables: €25 Mil
  • GF Value™: €2.98 vs. price of €2.52 (15.4% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the FRA:2CV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Convatec Group Business Description

Address 20 Eastbourne Terrace, 7th Floor, London, GBR, W2 6LG
Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 32% and 28% of total revenue, respectively. Continence care has become a slightly smaller business (22% of revenue) following the decision to exit the acute care market, and infusion sets contribute 18% of consolidated revenue.
77GF Score

Get the complete analysis for FRA:2CV

Other Current Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.52
Price
€2.98
GF Value